{"id":"grass-pollen-specific-immunotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (itching, swelling, erythema)"},{"rate":null,"effect":"Oral allergy syndrome (itching/swelling of mouth and throat)"},{"rate":null,"effect":"Systemic allergic reactions"},{"rate":null,"effect":"Rhinitis symptoms"},{"rate":null,"effect":"Asthma exacerbation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This immunotherapy works by administering gradually increasing doses of grass pollen extract to shift the immune response from IgE-mediated allergic reactions toward protective IgG and regulatory T cell responses. Over time, this process reduces allergic sensitivity and clinical symptoms upon natural grass pollen exposure. The mechanism involves both central tolerance induction and peripheral immune regulation.","oneSentence":"Grass pollen specific immunotherapy desensitizes the immune system to grass pollen allergens by gradually introducing increasing doses to induce immune tolerance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:20.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Grass pollen-induced allergic rhinitis and/or allergic asthma"}]},"trialDetails":[{"nctId":"NCT06876506","phase":"","title":"Identification of B Regulatory Cells by Flow Cytometry","status":"NOT_YET_RECRUITING","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2026-02-01","conditions":"Pollen Allergy, Venom Allergy","enrollment":80},{"nctId":"NCT01134757","phase":"NA","title":"Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction.","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2011-01","conditions":"House Dust Mite Allergy, Bronchial Hyperresponsiveness","enrollment":425},{"nctId":"NCT00133146","phase":"PHASE2","title":"Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine","status":"COMPLETED","sponsor":"Allergy Therapeutics","startDate":"2005-09-12","conditions":"Type I Hypersensitivity","enrollment":41},{"nctId":"NCT00133159","phase":"PHASE2","title":"Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen","status":"COMPLETED","sponsor":"Allergy Therapeutics","startDate":"2005-09-12","conditions":"Type I Hypersensitivity","enrollment":68},{"nctId":"NCT04389034","phase":"","title":"Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels","status":"COMPLETED","sponsor":"Allergy Therapeutics","startDate":"2020-04-22","conditions":"Rhinitis, Allergic, Respiratory Tract Infections, Allergy","enrollment":113},{"nctId":"NCT02423707","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2010-08","conditions":"Allergic Rhinitis","enrollment":110},{"nctId":"NCT01982474","phase":"PHASE1","title":"Safety of Lymph Node Injection for Allergen Immunotherapy","status":"UNKNOWN","sponsor":"Amber Patterson","startDate":"2013-10","conditions":"Allergic Rhinitis","enrollment":18},{"nctId":"NCT01350635","phase":"PHASE1, PHASE2","title":"Skin Test Study of BM32","status":"COMPLETED","sponsor":"Biomay AG","startDate":"2011-05","conditions":"Hypersensitivity","enrollment":60},{"nctId":"NCT00470457","phase":"PHASE2","title":"A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2001-06","conditions":"Rhinoconjunctivitis Due to Grass Pollen Allergy","enrollment":156},{"nctId":"NCT00841256","phase":"PHASE3","title":"Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2008-02","conditions":"Allergic Rhinoconjunctivitis","enrollment":207},{"nctId":"NCT01466465","phase":"PHASE2","title":"Vitamin D and Grass Pollen Specific Immunotherapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2011-10","conditions":"Allergic Rhinoconjunctivitis","enrollment":35},{"nctId":"NCT01085526","phase":"NA","title":"Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Allergic Rhinitis","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2010-02","conditions":"Allergic Rhinoconjunctivitis","enrollment":30},{"nctId":"NCT01353755","phase":"PHASE3","title":"2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2009-10","conditions":"Rhinoconjunctivitis, Allergic Asthma","enrollment":195},{"nctId":"NCT01830673","phase":"","title":"Regulatory T-cells After Subcutaneous Immunotherapy","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2011-10","conditions":"Grass Pollen Allergy, Specific Immunotherapy","enrollment":68},{"nctId":"NCT02156791","phase":"PHASE2","title":"Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM","status":"COMPLETED","sponsor":"BioTech Tools S.A.","startDate":"2013-08","conditions":"Hay Fever","enrollment":61},{"nctId":"NCT00263601","phase":"PHASE3","title":"Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2001-11","conditions":"Grass Pollen Allergy","enrollment":154},{"nctId":"NCT00813046","phase":"PHASE1","title":"Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis","status":"COMPLETED","sponsor":"BioTech Tools S.A.","startDate":"2008-12","conditions":"Seasonal Allergic Rhinoconjunctivitis","enrollment":8},{"nctId":"NCT01506375","phase":"PHASE2","title":"Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant","status":"COMPLETED","sponsor":"BioTech Tools S.A.","startDate":"2011-11","conditions":"Hay Fever","enrollment":24},{"nctId":"NCT00264459","phase":"PHASE3","title":"Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2003-02","conditions":"Grass Pollen Allergy","enrollment":160},{"nctId":"NCT00671268","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2008-03","conditions":"Rhinoconjunctivitis","enrollment":256},{"nctId":"NCT00666341","phase":"PHASE2","title":"Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2007-09","conditions":"Type I-Allergy","enrollment":50},{"nctId":"NCT00623701","phase":"PHASE3","title":"Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2008-03","conditions":"Allergy, Rhinitis, Conjunctivitis","enrollment":126},{"nctId":"NCT00227279","phase":"PHASE3","title":"A Trial of the ALK Grass Tablet in Subjects With Hayfever","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2004-10","conditions":"Allergy","enrollment":634},{"nctId":"NCT01728285","phase":"PHASE3","title":"Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2007-03","conditions":"Allergic Rhinitis, Grass Allergy","enrollment":261},{"nctId":"NCT01166269","phase":"PHASE2, PHASE3","title":"Study to Asses Efficacy of Intralymphatic Immunotherapy","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2010-07","conditions":"Allergy","enrollment":44},{"nctId":"NCT01523158","phase":"NA","title":"Mechanisms of Allergen Immunotherapy","status":"TERMINATED","sponsor":"Royal Sussex County Hospital","startDate":"2012-04","conditions":"Allergic Rhinitis","enrollment":2},{"nctId":"NCT01475188","phase":"PHASE4","title":"Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy","status":"COMPLETED","sponsor":"Ministry of Science and Higher Education, Poland","startDate":"2007-03","conditions":"Immunotherapy, Seasonal Allergic Rhinitis","enrollment":41},{"nctId":"NCT00833066","phase":"PHASE1, PHASE2","title":"Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis","status":"COMPLETED","sponsor":"BioTech Tools S.A.","startDate":"2009-02","conditions":"Seasonal Allergic Rhinoconjunctivitis","enrollment":54},{"nctId":"NCT01012531","phase":"PHASE3","title":"Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen","status":"COMPLETED","sponsor":"Roxall Medizin","startDate":"2008-10","conditions":"Allergic Rhinitis","enrollment":121},{"nctId":"NCT00719511","phase":"PHASE2","title":"Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2008-02","conditions":"Allergies","enrollment":132},{"nctId":"NCT00777374","phase":"PHASE2","title":"Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2008-10","conditions":"Allergic Rhinoconjunctivitis","enrollment":97},{"nctId":"NCT00104377","phase":"PHASE2","title":"Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen","status":"COMPLETED","sponsor":"Allergy Therapeutics","startDate":"2005-03","conditions":"Type I Hypersensitivity","enrollment":70},{"nctId":"NCT00241410","phase":"PHASE1","title":"Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen","status":"COMPLETED","sponsor":"Allergy Therapeutics","startDate":"2005-12","conditions":"Type I Hypersensitivity","enrollment":86},{"nctId":"NCT00104390","phase":"PHASE1","title":"Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing","status":"COMPLETED","sponsor":"Allergy Therapeutics","startDate":"2005-03","conditions":"Type I Hypersensitivity","enrollment":14},{"nctId":"NCT00457444","phase":"PHASE1","title":"Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2005-12","conditions":"Rhinoconjunctivitis","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Grass pollen specific immunotherapy","genericName":"Grass pollen specific immunotherapy","companyName":"Allergopharma GmbH & Co. KG","companyId":"allergopharma-gmbh-co-kg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Grass pollen specific immunotherapy desensitizes the immune system to grass pollen allergens by gradually introducing increasing doses to induce immune tolerance. Used for Grass pollen-induced allergic rhinitis and/or allergic asthma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}